This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Keytruda
  • /
  • Study of Pembrolizumab With or Without Platinum-ba...
Clinical trial

Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)

Read time: 3 mins
Last updated:14th Sep 2016
Identifier: NCT02853305

The purpose of this study is to determine the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy versus chemotherapy alone in participants with advanced or metastatic urothelial carcinoma (bladder cancer).

The primary hypotheses are that pembrolizumab plus chemotherapy is superior to chemotherapy alone with respect to Progression-free Survival (PFS) and Overall Survival (OS) in participants with programmed cell death ligand 1 (PD-L1) positive tumors (Combined Positive Score [CPS] ≥10%) and in all participants (includes those participants with PD-L1 positive tumors and those with PD-L1 negative tumors [CPS <10%]).

Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 990 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma
Actual Study Start Date: September 15, 2016
Estimated Primary Completion Date: June 1, 2019
Estimated Study Completion Date: May 31, 2020

- Experimental:
- Experimental: Pembrolizumab+Chemotherapy
- Active Comparator: Chemotherapy

Category Value
Date last updated at source 2018-06-08
Study type(s) Interventional
Expected enrolment 990
Study start date 2016-09-15
Estimated primary completion date 2019-06-01

View full details